EU Panel Recommends Merck’s WELIREG Combination for Kidney Cancer

The CHMP recommended approval of WELIREG plus lenvatinib for adults with advanced ccRCC after anti-PD-1/PD-L1 therapy. The European Commission is expected to decide within two months. Trial results showed a 26% reduction in PFS risk; overall survival did not reach statistical significance.